Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Premature closure of the arterial duct is a rare arterial duct anomaly, defined as a significant constriction or closure of the fetal arterial duct in the absence of structural heart defects with pathognomonic features of increased right ventricular afterload, tricuspid regurgitation and, consequently, right atrial dilation and right ventricular hypertrophy. The severity of symptoms is related to the degree and rate of ductal constriction and ranges from mild postnatal respiratory distress to development of ventricular failure with fetal hydrops and intrauterine death or severe cardiopulmonary compromise in the postnatal period. It may be associated with a prenatal exposure to cyclooxygenase inhibitors or corticosteroids.
Biomarker and diagnostic research for premature closure of the arterial duct has been reported in the published literature.
No clinical trials have been registered for premature closure of the arterial duct.
135 publications have been identified in PubMed for premature closure of the arterial duct. Research spans Clinical Trial Publication (33%), Epidemiology / Natural History (25%), and Review / Meta-Analysis (20%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 41 | 33% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 9:33 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Disease patterns and progression
31 |
25% |
Research summaries | 25 | 20% |
Patient case studies | 13 | 11% |
Laboratory research | 6 | 5% |
Testing and diagnosis research | 4 | 3% |
New treatment approaches | 2 | 2% |
Other research | 1 | 1% |
Simpson MK (2026). [PMID: 39812796](https://pubmed.ncbi.nlm.nih.gov/39812796/). *Pediatr Cardiol*. [Clinical Trial Publication]
Rozé JC (2026). [PMID: 41697673](https://pubmed.ncbi.nlm.nih.gov/41697673/). *JAMA Pediatr*. [Clinical Trial Publication]
Parikh NA (2026). [PMID: 41568452](https://pubmed.ncbi.nlm.nih.gov/41568452/). *Curr Opin Pediatr*. [Review / Meta-Analysis]
Giannopoulou E (2026). [PMID: 41694839](https://pubmed.ncbi.nlm.nih.gov/41694839/). *Cureus*. [Case Report / Case Series]
Arriaga-Redondo M (2026). [PMID: 42162517](https://pubmed.ncbi.nlm.nih.gov/42162517/). *Eur J Pediatr*. [Epidemiology / Natural History]
Adelheid K (2026). [PMID: 42156592](https://pubmed.ncbi.nlm.nih.gov/42156592/). *Eur J Pediatr*. [Clinical Trial Publication]
Kaluarachchi DC (2026). [PMID: 40987835](https://pubmed.ncbi.nlm.nih.gov/40987835/). *J Perinatol*. [Clinical Trial Publication]
Saini A (2026). [PMID: 40192760](https://pubmed.ncbi.nlm.nih.gov/40192760/). *Pediatr Cardiol*. [Review / Meta-Analysis]
Ieno L (2026). [PMID: 41802915](https://pubmed.ncbi.nlm.nih.gov/41802915/). *J Matern Fetal Neonatal Med*. [Gene Therapy / Novel Therapeutics]
Gillam-Krakauer M (2026). [PMID: 28613509](https://pubmed.ncbi.nlm.nih.gov/28613509/). *Unknown Journal*. [Diagnostic / Biomarker]